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Obstruction: Status in 1986
P.G. Hugenholtz, M.D., P.W. Serruys, M.D., M.L. Simoons, M.D.,
and J. Lubsen, M.D.
The effect of thrombolysis in acute myocardial infarction on
enzymatic infarct size, left ventricularfunction, and early mortality was
studied in subsets ofpatients in a randomized trial at The Netherlands
Interuniversity Cardiological Institute during a 5-year period. Early
thrombolytic therapy with intracoronary streptokinase (152 patients) or
with intracoronary streptokinasepreceded by intravenous streptokinase
(117 patients) was compared to conventional treatment (264 patients).
All 533 patients were admitted to the coronary care unit within 4 hours
after onset ofsymptoms indicative ofacute myocardial infarction. There
were 488 patients eligiblefor this detailed analysis, ofwhom 245 were
allocated for thrombolytic therapy. Early angiography was performed
in 212 of the 245 patients. Patency of the infarct-related artery was
achieved in 181 patients (85%). Enzymatic infarct size measuredfrom
cumulative alpha HBDH release was smaller in patients allocated to
thrombolytic therapy (median 760 Ull vs. 1179 Ull in controls, p =
0.0001). LVEF measured by radionuclide angiography before discharge
was higher after thrombolytic therapy (median 50% vs. 43% in controls,
p = 0.0001). The 12-month mortality was lower in patients allocated
to thrombolytic therapy (8% vs. 16% in the control group, p < 0.01).
In multivariate regression analysis, infarct size limitation, improvement
ofLVEF, and a 3-month mortality were predicted by ST, timefrom onset
ofsymptoms to admission, and Killip class at admission. Thrombolysis
was most useful in patients admitted within 2 hours after onset of
symptoms and in patients with STof1.2 mVor more. On the other hand,
no beneficial effects of streptokinase on enzymatic infarct size, left
ventricularfunction, or mortality were observed in the subset ofpatients
with STless than 1.2 mVadmitted2 to4 hours after onset ofsymptoms.
In the long term, improved survival and enhanced quality of life are
most evident after thrombolytic therapy in patients with larger anterior
wall infarction, and less pronounced in patients with smaller inferior
wall infarction. (Texas Heart Institute Journal 1986; 13.433445)
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INTHE LASTTWO decades, coronary care
units (CCU) have made it possible to recog-
nize and expeditiously treat previously fatal
arrhythmias during the acute stage of myocar-
dial infarction. This has reduced the in-hospi-
tal mortality rate from + 30% to < 15%. At
the same time it has become evident that pump
failure, arising from such factors as ventricular
dysfunction and acute cardiogenic shock, is
now the leading cause of death. Efforts at tem-
porary mechanical or pharmacological support
of the heart have been largely unsuccessful, so
attention is now directed towards prevention of
ventricular failure and limitation of the
myocardial infarct size, or even towards out-
right prevention of infarction itself. Although
data from experimentation with a variety of
pharmacologic agents seemed promising,
recent large-scale clinical trials with the early
administration of beta blockers1 2 and calcium
antagonists3-6 have shown no major reduction
in mortality, and this has helped to refocus
attention on earlier reperfusion efforts with
streptokinase, a powerful thrombolytic agent.
The relevance of attempts to improve left ven-
tricular funtion by reducing the amount of tissue
lost to infarction is evident when one considers
the general relationship between post-infarc-
tion left-ventricular ejection fraction, a gen-
eral expression of left-ventricular function,
and one-year mortality. It also shows the
benefits that may be expected if ventricular
function can be maintained or improved.
The causal thrombosis in acute myocardial
infarction has for a long time been a matter for
debate. Although it had been assumed since
Herrick's days that thrombosis was always the
cause of an infarction, careful postmortem
studies in the sixties cast doubt on this theory
because many patients showed infarction with-
out complete obstruction. Some researchers
postulated, therefore, that thrombosis was the
sequel of infarction. Such theories, based on
postmortem examination, were corrected
through the detailed anatomic studies of Ful-
ton et a17 and were corroborated by DeWood
et al,8 who showed by coronary arteriography
that, in the first few hours after myocardial
infarction, thrombosis was present in nearly
all cases. In 517 patients studied within 4 hours
after onset of symptoms, they found a com-
plete obstruction in 86%. These data were con-
firmed in the recent large trial carried out by
the Netherlands Interuniversity Cardiological
Institute,9 a trial that indicated complete
obstruction in 84% of 264 patients who were
randomized to early angiography and intra-
coronary thrombolysis (Table I). Similar data
were found by others. 10-15
These observations, therefore, bring three
fundamental concepts into focus: first, angiog-
raphy can be carried out in acute myocardial
infarction without major risks; second, throm-
bosis is present in the majority of patients
when they are studied within the first few
hours after symptoms; and third, the preva-
lence of complete obstruction declines as the
time after the onset of symptoms lengthens.
Indeed, obstruction was found in only 60% of
patients when the interval after onset of
symptoms exceeded 6 hours, corresponding to
the observations of the pathologists who had
found, on average, complete obstruction in
only half of all cases, which were usually
studied at 6 to 24 hours after onset of
symptoms or death. It is therefore likely that
only in those patients who present at an early
stage of acute myocardial infarction can infarct
size be limited by an approach aimed at
desobstruction. Furthermore, from the experi-
ments carried out by Sobel's group, lS it is evi-
dent that early reperfusion not only limits the
ultimate infarct size but also achieves a return
to normal cardiac function and metabolism.
Thus all available evidence points towards the
need for early desobstruction.
The feasibility of rapid dissolution of intra-
coronary thrombi by systemic or selective
infusion of thrombolytic substances has been
convincingly demonstrated in experimental
series and in clinical pilot studies for the past
quarter-century.' 6-21 This has led to wide-
spread trials using streptokinase, which was
given intravenously in varying doses and at
varying time intervals, mostly with disappoint-
ing or insignificant results. This initial failure
of streptokinase can now be explained by the
facts that the series were too small, the patient
selection and evaluation techniques were
flawed, and the statistical design was old-
fashioned, but mainly by the fact that strep-
tokinase was administered too late. In particu-
lar, no attempts were made to prove patency of
the infarct-related artery by angiography nor to
measure infarct size. The older experience
should therefore be eliminated from current
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considerations, although Yusuf et a122 con-
clude from a pooled analysis of some 6,000
patients in 24 randomized trials with intra-
venous streptokinase that a reduction in the
odds of death by 22 + 5% can be deduced.
This entire field has now been changed
radically by the data from the GISSI-trial,23 an
all-Italian study, which has shown a highly
significant reduction in mortality in those
patients who were treated within the first 3
hours after onset of symptoms (Table II).
Because of the large numbers involved in this
trial, these mortality statistics are convincing.
It was not, however, until 1979 that the
systematic effort at restoration of anterograde
flow after intracoronary streptokinase admin-
istration was introduced into clinical practice
by Rentrop and other workers in Ger-
many.21'24'25 Since then, we have witnessed a
dramatic increase in the number of patients
with acute ischemic cardiac disorders who
have been treated by intracoronary strep-
tokinase infusion,22 25-27 and the results have
given new color to the cheeks of those who
advocated the intravenous route prior to
GISSI. A more widespread and thoroughgoing
application of the new technique-combining
the advantages of early intravenous adminis-
tration with intracoronary clot lysis and the
follow-up treatment of residual coronary
artery obstruction (with PTCA or bypass
surgery)-now appears to be justified in
medical centers capable of executing it.
Benefits and risks have recently, and ade-
quately, been investigated. Furthermore, the
technique is entirely consistent with experi-
mental evidence.26'28'29
In a 1982 editorial reviewing the literature
up to that year, Rentrop and I urged caution
against too much early enthusiasm. We
pointed to the main factors that could influence
the ultimate outcome: the need to know the
time interval between onset of symptoms and
desobstruction; the extent of restoration of
myocardial function in the region perfused by
that artery; the availability of functional
collateral flow; the best route for and the
optimal amount of thrombolytic agents; the
best agent; agents' side effects; and the degree
to which the usual sequelae of myocardial
infarction, such as subsequent angina, rein-
farction and death, can be reduced when
TABLE II. Data from the GLISSI Trial
Involving 11,483 Patients,
Oct. 1985 (Tognoni)
Hospital IV SK Controls Difference
mortality 5,756 5,727 p-value
:1 hr 8.1% 15.3% <0.002
-3 hrs 8.5% 11.9% <0.001
3-6 hrs 11.3% 12.9% N.S.
12 hrs 10.6% 12.9% <0.02
First Ml 9.7% 12.0% <0.01
Re-infarction 180 92 <0.001
Pericarditis 325 565 <0.001
LV failure 583 671 N.S.
streptokinase recipients are compared to a
control group randomly assigned to conven-
tional treatment. These arguments have
recently been repeated by Yusuf et al, 22
although their conclusion regarding the need
for giant trials with thousands of patients to
answer these questions is debatable. So long
as the true pathophysiological basis for treat-
ment has not been sufficiently clarified, and in
fact grows less clear as the ischemia evolves
(a function of the available collateral supply,
among other factors), it would seem unwise to
lump together patient groups with widely
varying characteristics in an effort to reach
some form of statistical significance. Rather,
we should direct our efforts at therapeutic
intervention for specific derangements.
Returning to the editorial question (quo
vadis?),30 what have we learned from the
smaller series and from incidental observa-
tions in the years since 1980?
Most importantly, recanalization, whether by
guidewire alone30'3' or by clot lysis with
streptokinase 9,15,26,32,33 urokinase34 or
recombinant tissue plasminogen acti-
vator, 12535-37 has now been shown to limit
infarct size, provided it is carried out within
the first few hours after onset of occlusion. On
the other hand, Reimer et a138 and others have
confirmed in many animal models that after 6
hours of complete ischemia, the amount of
salvageable myocardium is insignificant.
Bergmann et a139 have confirmed these find-
ings in closed-chest dogs, employing positron
emission tomography to assess'1 C-palmitate
uptake reperfused myocardium. Salvageable
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Fig. 1 Development of infarct size as percentage of the "infarct size" that would occur when the coronary artery
is permanently occluded. Schaper29 has shown that in various animal species infarct size varies greatly despite
similar occlusion periods. Enzymatic estimation of infarct size in patients after thrombolytic therapy shows that
occlusions of less than 30 minutes usually do not lead to substantial loss of myocardial tissue. Occlusions of 2
hours lead to approximately 50% of the ultimate infarct size, while occlusions up to 4 hours result in 80% of the
ultimate infarct size. If we suppose that thrombolysis will occur 30 minutes earlier, when streptokinase or rt-PA
is given in the ambulance, approximately one-eighth of the ultimate infarct size will be prevented, in addition to
that demonstrated in the studies of the Interuniversity Cardiological Institute in the Netherlands.9
myocardium increased by 76%, as opposed to
15%, when reperfusion was carried out within
2 hours after occlusion rather than within 2 to
4 hours. These and other studies, however,
were performed with animals; since it is now
generally accepted that the functional charac-
teristics of their coronary circulations differ
significantly from those of man, it has become
clear that no animal model can completely
mimic the human situation.29,39,40 Neverthe-
less, all these data support the concept that
reperfusion must be established soon after
occlusion, for no major beneficial effects can
be expected beyond 3 to 4 hours after onset of
ischemia (Fig. 1). While data from the pooled
analysis by Yusuf22 suggest that some statisti-
cal benefit cannot be excluded when treatment
is started late, the numbers are not convincing,
and recent data from the GISSI trial indicate
actual damage by late therapy23 (Table II).
Rentrop et al,41 Schwarz et al,42 and Schroder
et al43 have also found that while the extent of
salvage is less when therapy is started beyond
the fourth hour after onset of symptoms, late
recanalization may still result in some
improvement, particularly in those patients in
whom collateral circulation is demonstrable
by acute angiography. It is likely that, in these
patients, the evolution of myocardial necrosis
("stuttering necrosis") is slowed when collat-
eral flow is enhanced early. The Netherlands
data have shown the best improvement in
cardiac function, smallest infarct size and
lowest mortality in the subset of 117 patients
in whom intracoronary clot lysis was pre-
ceded by intravenous streptokinase. In these
patients, lysis was begun at a median of 3
hours after onset of symptoms. Angiography
before the start of subsequent intracoronary
streptokinase showed a patent coronary artery
in fewer than half of these cases, however.
This finding therefore supports the notion that
lytic therapy works not only through desob-
struction of the main infarct-related vessel but
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also through improved rheology and reduced
viscosity, benefiting the collateral bed. In
keeping with this is the fact that enzyme
washout was highest in those patients who
were treated earliest, but also occurred in
those in whom the infarct-related vessel
remained closed. The GISSI data,23 which
show a significant mortality reduction after
intravenous administration only within 3 hours
of symptom onset, together with the Nether-
lands data that show a drastic reduction in
mortality for the intravenous plus intracoronary
streptokinase group, confirm for the first time
the thesis recently proposed by Verstraete44
that intravenous administration is "the only
way." There is, however, one essential condi-
tion: intravenous thrombolysis within 1 to 3
hours will not alone "fill the bill" when signs
of ischemia persist or return. This will be the
case in many, if not half, the cases because of
the underlying atheromatous lesion. So the
"only way" has to be modified (Fig. 2).
To clarify these issues, a large-scale investi-
gation into the relevance of intracoronary
administration of streptokinase was begun in
1980 at the Thoraxcenter in Rotterdam and
expanded to three other centers, so that by
March 15, 1985, we were able to include 533
patients in a randomized study.9 This figure
excludes our earlier pilot trial of 82 patients,
whose results in fact mimic those of the
randomized trial. Half of the patients (264 of
the Netherlands Interuniversity Institute Trial)
were allocated to conventional treatment in the
CCU and the other half (269) to an attempt at
reperfusion. Of these 269 patients, 152 were
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Figs. 2a, b, c, d A case where everything went according to plan (optimal reperfusion within 4 hours after onset
of symptoms). Figures show sequence of events.
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assigned to streptokinase therapy by the
intracoronary route only, with 117 receiving
500,000 units of streptokinase intravenously,
an average of 100 minutes prior to intracoro-
nary administration. This second group was so
treated when experience showed us that a
significant delay persisted during preparation
of the catheterization laboratory and before
introduction of catheters. In more than 80% of
the total trial group, therapy was begun within
3 hours after onset of symptoms. It was shown
that mortality at 14 days was 5% in the group
assigned to thrombolysis (14 out of 269)
versus 9% in the group assigned conventional
therapy (25 out of 264), and that at a median
of 8 months, mortality was 9% versus 16%, a
highly significant reduction (p < 0.01) (Table
I). As stated earlier, the mortality in the
intravenous plus intracoronary group was even
lower than in the overall group of reperfused
patients. Best results were achieved when
spontaneous lysis cases were added to those
with lysis and PTCA-one death out of 98
cases in one year, an observation strongly
supporting the hypothesis that early and
complete revascularization by whatever
means is essential. Furthermore, cardiogenic
shock, CHF, ventricular fibrillation, and
pericarditis were half as frequent in the group
assigned to thrombolysis (Table I) (Fig. 2).
In addition, enzyme (alpha HBDH) release
was 30% lower in the treated group, indicating
a smaller size of the ultimate infarct. Smaller
infarct size was also indicated by a marked
improvement in left ventricular ejection frac-
tion, which was significantly higher in the
treated group than in the control group (53%
versus 46%). In the latter group, furthermore,
end-diastolic and end-systolic volumes were
normal. In addition, experience throughout
the study was gained with percutaneous trans-
luminal angioplasty (PTCA), which was
carried out in those patients who, after initial
reperfusion, showed significant residual
coronary artery obstruction or reocclusion
while still in the catheterization laboratory. In
this subgroup of patients, further reduction of
the one-year mortality rate was achieved. It is
of interest to look at other data collected
during the same time span at the Thoraxcenter
in patients with unstable angina, a condition
that may be considered to be a precursor of
acute myocardial infarction. In 136 patients
who had been refractory to intense, often
triple, pharmacological treatment, aggressive
treatment with PTCA reduced one-year mor-
tality to a low 1%, with low recurrence of
angina or infarction. This indicates the desira-
bility of "cleaning up" the obstruction when
symptoms of ischemia persist, regardless of
whether prior treatment was vasodilating or
thrombolytic. It is the underlying atheroma-
tous obstruction that must be reduced. In this
regard we emphasize the comments by Ver-
straete44 that "critical narrowing continues to
be a threat to the patient, even after early
reestablishment of anterograde flow." The
results in the 533 Dutch patients demonstrate
that a strategy aimed at early recanalization of
the infarct-related artery by both intravenous
and intracoronary administration of strep-
tokinase can indeed improve both clinical
course and survival rate in the first year after
myocardial infarction.
While earlier analysis of pooled data from
randomized trials of intracoronary streptoki-
nase (including preliminary data from the now
completed Netherlands study) indicated no
major beneficial effects on survival,22 the
current Netherlands data,9 and the GISSI
data,23 show convincing evidence that throm-
bolysis by streptokinase can result in a striking
reduction of mortality in acute myocardial
infarction, as a result of smaller infarct size
and better residual left ventricular function,
provided such therapy is initiated early, i.e.,
within 4 hours after the onset of symptoms.
Since the Italian and Dutch trial results are
all based on the "intention-to-treat principle"
and on a random assignment procedure, early
reperfusion of the obstructed coronary artery
in acute myocardial infarction can now be
recommended in health care systems where
the conditions outlined above can be met. In
Western Germany 66% of the population45
now have access to such facilities, while in the
Netherlands at least 75% have similar access,
provided adequate referral arrangements are
made. Furthermore, subset analysis of the
Western Washington trial,'4 the only other
large-scale randomized trial, has indicated that
patients treated early benefit from similar
reductions in mortality rates. Added to these
trials are non-randomized studies such as those
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carried out in Germany (Aachen, 461
patients;46 Mainz and Heidelberg, + 700
patients taken together;46 and Hamburg and
Berlin, over 1,000 taken together47) and by the
French collaborative group ( + 1,000
patients48), all of which indicate that a marked
reduction in mortality, with improvement in
ventricular function, can be demonstrated in
those patients in whom early reperfusion was
achieved, particularly when compared to early
efforts at "permanent" recanalization.
The entire field has been enormously stimu-
lated by the development of still better agents
to lyse the thrombus. In his 1979 Edward
Kowalski memorial lecture,49 Collen pre-
sented evidence that plasminogen activation
could occur in several different pathways.
Shortly afterwards, Collen and Verstraete50
argued in favor of tissue-type plasminogen
activator for systemic thrombolytic therapy.
This in turn led to several trials, one of
which was published in 1985 by Verstraete et
al,35 who reported from the European
Cooperative Study Group that in 64 patients
treated with recombinant tissue plasminogen
activator (rt-PA) the frequency of coronary
patency was found to be higher (72%) than
after intravenous streptokinase (55%). A
second study just published shows that when
rt-PA is compared to placebo by angiographic
documentation, the former achieves patency
in 38 out of 62 patients (61%), versus the
placebo in 13 out of 62 (21%), although there
was a 6-hour delay in onset of therapy.
These and trials currently in progress indi-
cate that all inferences based on current
evidence from "the best" intravenous strepto-
kinase trials (Yusuf et al16) can be expected to
be even more promising with infusion of rt-PA.
The earlier thesis, amended by Verstraete44
- that the intravenous route of early drug
administration is the only realistic one, but
will require in a certain subset further therapy
of "critical narrowing"-appears therefore to
be confirmed, although still more recent
evidence indicates that the rapid activity of
rt-PA may lead to higher reocclusion rates after
initial success. In 20 patients treated with rt-PA,
Gold et al5l found early reflow in 80%, but
reocclusion despite heparinization in 37%,
one hour after cessation of rt-PA infusion.
This, in turn, strengthens our previous argu-
ments9 52 that if relief of ischemic signs is not
complete within 2-4 hours after intravenous
rt-PA, or for that matter after administration of
any other agent, intracoronary manipulations
remain mandatory, since myocardium is
jeopardized from the first few minutes of
ischemia-on.53'54 The short duration of rt-PA
action is an advantage, not only because of the
limited suppression of systemic fibrinolysis,
but also because of the increased chance this
affords for surgical intervention when obstruc-
tion persists on the basis of the underlying
residual atheromatous lesion.
CONCLUSIONS
1. Thrombus formation is present in + 85%
of all patients who present within the first
four hours after the onset of acute myocar-
dial infarction. It is the cause of infarction.
2. While the thrombus may lyse spontane-
ously, this usually occurs after the fourth
hour, by which time the interruption of
blood supply most often has led to perma-
nent damage of myocardial tissue.
3. Coronary angiography and intracoronary
manipulations can be carried out without
undue complications, provided that
trained personnel and suitable facilities
are available.
4. Intracoronary streptokinase, preferably
preceded by intravenous streptokinase, is
currently the most effective method to lyse
a thrombus, provided it is administered
early after the onset of symptoms. It has
halved the one-year mortality rate from 15.9
to 8.5% in the recent Netherlands trials.
5. Intravenous streptokinase given within
0-3 hours of onset of symptoms can
achieve similiar results (GISSI trial).
6. Intracoronary adminstration must there-
fore be considered a sequel to intravenous
therapy, when recanalization by the intra-
venous route (achieved on average in only
50-55% of cases) has not alleviated ische-
mia. Although rheologic factors (opening
of collaterals, decreased viscosity) may
already be beneficial, even when the main
obstruction has not yet been resolved,
they are of secondary importance.
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7. It has been shown that when residual
stenosis is detected by clinical signs (such
as recurrence of pain, ST-segment eleva-
tion or increases in CPK release) early
PTCA or CABG can achieve optimal
recanalization, ultimately reducing one-
year mortality to a few percent.
8. Early reperfusion will lead to smaller
infarct sizes55'56 and maintained left
ventricular function,57 thus explaining
the much improved prognosis and sur-
vival rates.9
9. Thus far the reported data from rt-PA
indicate it to be superior to intravenous
streptokinase. Although reocclusion rates
are higher than with streptokinase,5 early
PTCA has been advocated and has proved
successful.58 It may well be the agent of
the future.
10. Early PTCA and bypass surgery without
prior pharmacological lysis has shown
similar benefits in selected centers, but
is costly.
11. Determining whether the full benefits of
these new strategies can be given to the
majority of patients with acute infarction
will be more a matter of improving exist-
ing coronary care facilities to permit rapid
detection, referral, and admission, than of
finding the optimal reperfusion therapy.
While these conclusions indicate that early
reperfusion must be recommended in all
patients with suspected acute myocardial
infarction for the desired reduction in unneces-
sary death, many practiced restrictions
remain.30,59,60 The need for cardiac catheteri-
zation in perhaps more than 50% of cases, in
order to verify the quality and the extent of
recanalization, particularly in those patients
where residual signs of ischemia persist, can
be met only in appropriately equipped cen-
ters.61 Furthermore, the inevitable delays in
recognition of symptoms, the need to call the
appropriate authority or the physician, the
delay in transport, the limited availability of
catheterization laboratories or operating
rooms on permanent standby, all will influence
the effectiveness of such an approach. There-
fore, if a simple intravenous thrombolytic
agent were available-currently human tissue
rt-PA is a leading candidate-or ifan improved
streptokinase derivative (BRL.26922) were to
be proved effective, together with aggressive
anti-ischemic therapy such as the administra-
tion of an effective beta blocker in combina-
tion with a calcium antagonist (atenolol in
combination with nifedipine would on theo-
retical grounds be the leading contender)62'63
or with an afterload-reducing agent such as
captopril, then the scheme discussed above
will gain attractiveness. If rt-PA, which is a
natural activator of the fibrinolytic system
presently reproduced by a recombinant DNA
technique, were to become available on a large
scale and if the early data12'35 that indicate up
to 7% reperfusion within 1 to 4 hours after
intravenous administration of rt-PA were to be
confirmed, these developments would cer-
tainly revolutionize the treatment of acute
myocardial infarction. A European trial with
rt-PA is now proposed to judge its efficacy on
patients given one of three alternative treat-
ments for acute myocardial infarction: 1) con-
ventional treatment with intravenous rt-PA;
2) intravenous rt-PA followed by coronary
angiography and, where needed, by PTCA; or
3) conventional CCU treatment with placebo.
Results to be studied are ventricular function,
infarct size, and mortality. If these are posi-
tive, we can conceive a future in which this
plasminogen activator, combined with cardio-
protective agents, will be widely administered
by general practitioners and ambulance ser-
vices within the first few hours after the onset
of acute myocardial infarction (Fig. 3). Upon
admission to the CCU within 4-6 hours, those
patients with residual ischemic signs would be
catheterized with the aim of permanent
recanalization by PTCA or bypass surgery.
The other ("cooled off') cases would not need
any urgent intervention. Proof of the efficacy
of such a strategy lies in application of this
scheme to all patients suffering from acute
myocardial infarction in a given health region.
For example, such a large-scale approach
could be applied to cities the size of Seattle or
Rotterdam, with "modest" populations of
600,000. Well organized transport systems
and properly distributed health care centers
that have already proved their vaiue in reduc-
ing sudden death in these cities could serve as
the underlying support.
Accordingly, a Rotterdam study has now
been proposed to investigate whether such a
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R E P A I R F L O W C H A R T
40 CCU BEDS:
GIVE ONLY I.V. REPAIR
IF NO RESULT
*
20 CCU BEDS: CONTINUE I.V.
OR-BEGIN I.C. REPAIR
IF NO RESULT
*
I.C. THROMBOLYSIS + PTCA, as needed + CABG, as needed.
Fig. 3 Flowchart of potential study to be carried out world wide. Based on 1984 transport and referral data. It is
estimated that up to 3,000 patients would arrive in the system on time to begin REPAIR (Reperfusion Acute
Infarction Rotterdam).
large-scale attack on acute myocardial infarc-
tion is possible on the basis of currently
existing facilities (Fig. 3). It will require the
participation of all general practitioners (280
for + 600,000 inhabitants), of the centralized
ambulance service, and of existing hospital
facilities. From an economic viewpoint, the
ultimate hope is that if myocardial infarction
can be limited in size or avoided altogether,
with a consequential halving of the death rate,
the cost savings from avoiding expensive post-
myocardial infarction intervention measures
alone, such as treatment of cardiogenic shock
or CHF, could easily outweigh the modest
increase in initial costs required by early
treatment.64 If this proves correct, both the
quality and the duration of life after infarction
can be improved at acceptable cost.
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